Strokes with sickle cell disease: Dynamic interplay between biomechanical and biochemical stimuli

Manu O. Platt, Ph.D.

Director, Center for Biomedical Engineering Technology Acceleration (BETA)

Senior Investigator, NIBIB

Head, Mechanics and Tissue Remodeling In Computational & Experimental Systems (MATRICES)

NIH Distinguished Scholar

Associate Director for Scientific DEIA, NIBIB


Seminar Information

Seminar Date
January 10, 2025 - 2:00 PM

Location
The FUNG Auditorium - PFBH

manu o platt

Abstract

Of children born with sickle cell disease, 11% will have a major stroke by age 16, and 30-35% will have a silent stroke impairing cognitive abilities. Later in life, risk for hemorrhagic stroke increases, suggesting an age-related component to arterial damage. Significantly higher velocities measured with transcranial Doppler in cerebral arteries implicates children at risk for strokes with disturbed cerebral hemodynamics. Cathepsins are a family of proteases containing the most potent human elastases and collagenases that we have shown to be upregulated by disturbed blood flow and by inflammatory stimuli, known to be elevated in sickle cell disease. It is unclear, however, how biomechanical and biochemical stimuli integrate to accelerate pathological remodeling of large arteries in these children. We will present our multiscale approach and results demonstrating these links between disturbed blood flow and chronic inflammation due to sickle cell disease, from the cellular level to transgenic animal models up through human computational fluid dynamics to identify new targets to prevent this accelerated artery damage affecting those born with this genetic disease and aging related implications.

 

Speaker Bio

Dr. Manu Platt received his B.S. in Biology from Morehouse College and Ph.D. from Georgia Tech/Emory in Biomedical Engineering. After a postdoc at MIT, he returned to Georgia Tech/Emory Coulter Department of Biomedical Engineering where he advanced to full Professor. His research program focuses on proteolytic mechanisms of disease, translational approaches to reduce strokes in people affected by sickle cell disease, and harnessing proteolytic networks and systems biology tools to predict disease progression. Integrated with research are mentoring goals of changing the look of the next generation of scientists and engineers through successful diversity programs he initiated. In 2023, Dr. Platt became the inaugural director of the NIH-wide Center for Biomedical Engineering Technology Acceleration (BETA Center), housed within the National Institute of Biomedical Imaging and Bioengineering (NIBIB). He is a Fellow of AIMBE, Fellow of BMES, The Root 100 in 2019, and AAAS Mentor Award in 2021.